HeyJaredJaymin Kang
- Indexed articles, last 90 days
- 82
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Cancer Therapy Advisor
- Top 5M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
FDA Approves Imatinib Oral Solution Imkeldi - Oncology Nurse Advisor (opens the original)
Read excerpt
The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution formulation of imatinib. Imkeldi is indicated to treat chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases, and gastrointestinal stromal tumors as well as aggressive systematic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to all
Mounjaro Approved to Reduce MACE Risk in Adults With T2DM (opens the original)
Read excerpt
The Food and Drug Administration (FDA) has approved Mounjaro® (tirzepatide) to reduce the risk of major adverse cardiovascular (CV) events (MACE; CV death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus (T2DM) who are at high risk for these events. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The approval was based on data from the randomized, double-blind,
FDA Authorizes First Continuous Dual Glucose-Ketone Monitoring Device (opens the original)
Read excerpt
The Food and Drug Administration (FDA) has authorized the Libre Duo 10 Day system, a dual glucose and ketone sensing biowearable for patients aged 2 years and older with diabetes. The system continuously tracks both ketone and glucose levels from a single sensor and is intended for patients with type 1 or type 2 diabetes who use insulin or other glucose-lowering medications. By delivering real-time alerts wirelessly to a smartphone when ketones are elevated, the system allows for early intervent
FDA Approves Updated 2026-2027 COVID-19 Vaccines (opens the original)
Read excerpt
The Food and Drug Administration (FDA) has approved an updated formulation for Comirnaty® (COVID-19 vaccine, mRNA; Pfizer/BioNTech), Spikevax® (COVID-19 Vaccine, mRNA; Moderna), mNEXSPIKE® (COVID-19 Vaccine, mRNA; Moderna), and Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted; Novavax) for the upcoming 2026-2027 vaccination season. In May 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee recommended all 2026-2027 COVID-19 vaccines be formulated against the XFG variant, a JN.1 l
FDA Approves Updated 2026-2027 COVID-19 Vaccines (opens the original)
Read excerpt
The Food and Drug Administration (FDA) has approved an updated formulation for Comirnaty® (COVID-19 vaccine, mRNA; Pfizer/BioNTech), Spikevax® (COVID-19 Vaccine, mRNA; Moderna), mNEXSPIKE® (COVID-19 Vaccine, mRNA; Moderna), and Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted; Novavax) for the upcoming 2026-2027 vaccination season. In May 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee recommended all 2026-2027 COVID-19 vaccines be formulated against the XFG variant, a JN.1 l
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Cancer Therapy Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.